Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 12;7:11408. doi: 10.1038/s41598-017-11628-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

DXN and its principal component Valeriana jatamansi (Vj) delayed worm paralysis similarly, but it could not be reduced due to its safety. (A) Paralysis assays for the temperature sensitive Aβ strain CL4176 treated with DXN or other herbs of Ra, Ru and Vj. Data are the average of three replicates with about 180 worms in each group. ***Indicated that there was significant difference between treatment group and control group at P < 0.001. (B) The effects of DXN and Vj on the body length of AD worms tested. The concentration of herb of Ra, Ru and Vj was equivalent to each of them containing in DXN. There is significant difference among these groups when symbols are different (P < 0.05). (C) Paralysis assays for the temperature sensitive Aβ strain CL4176 treated with DXN from the onset of paralysis. Data are the average of three replicates with about 180 worms in each group. ***Indicated that there was significant difference between treatment group and control group at P < 0.001. (D) The effect of DXN on Vj on GFP expression in smg-1[myo-3p::GFP] worms. (E) The relative mean fluorescence intensity of worms treated with or without drugs. Data are the average of three replicates with about 90 worms in each group. The scale bar was 40 μm.